How Japanese drugmaker Takeda's $62b Shire deal reshapes pharma world

FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018. REUTERS/Kim Kyung-Hoon - RC1702FA7D40/File Photo

The rapidly changing global pharmaceutical landscape reached another milestone Tuesday as Takeda Pharmaceutical Co. completed its $62 billion acquisition of Shire Plc.

Takeda’s purchase was the world’s biggest announced acquisition of 2018, transforming the 237-year-old Japanese company into a top 10 drugmaker with lucrative therapies for rare diseases and a sizable footprint in the U.S.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter